文献速递炎症性肠病

去岩藻糖基化Fc区的抗肿瘤坏死因子抗体在结肠炎小鼠中疗效增强

Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.
PubMed 文献 · Gastroenterology · 2017-07-27

该研究探讨抗TNF抗体Fc区与Fcγ受体的相互作用,以及去除Fc核心岩藻糖(增加与FcγRIIIa结合)是否增强抗TNF在小鼠结肠炎中的疗效。结果显示,FcγR engagement是抗TNF减轻小鼠结肠炎和诱导CD206+巨噬细胞所必需的;去岩藻糖基化阿达木单抗以更高亲和力结合FcγRIIIa,在体外和体内均更有效。

要点

  • 抗TNF减轻小鼠结肠炎和诱导CD206+巨噬细胞需要FcγR engagement。
  • 去岩藻糖基化阿达木单抗以更高亲和力结合人FcγRIIIa。
  • 去岩藻糖基化抗TNF在结肠炎小鼠中更有效减轻组织学严重程度。

核心结论

  • 抗TNF减轻小鼠结肠炎和CD206+巨噬细胞发育需要FcγR engagement。
  • 去岩藻糖基化抗TNF以更高亲和力结合FcγRIIIa,并在人PBMCs中诱导CD206+巨噬细胞发育,尤其是表达低亲和力FcγRIIIa的PBMCs。
  • 去岩藻糖基化抗TNF可能对炎症性肠病患者更有效。

研究设计与样本

  • 研究为体外和体内机制研究,使用Rag1-/-小鼠、缺乏所有激活型FcγR的FcγR-/-Rag1-/-小鼠、CD4+CD45RBhi T细胞转移诱导的结肠炎模型,以及健康供者外周血单个核细胞(PBMCs)。
  • 产生针对小鼠和人TNF的低岩藻糖基化抗体(阿达木单抗),并给予不同抗TNF抗体或同型对照抗体,测定疾病活动指数评分和组织学分析。
  • 在人PBMCs混合淋巴细胞反应中测量T细胞增殖和CD206+巨噬细胞比例,并用TaqMan单核苷酸多态性基因分型检测FCGR3A158。

主要发现

  • 给予抗TNF的Rag1-/-结肠炎小鼠接近完全黏膜愈合,而给予同型对照抗体的Rag1-/-小鼠发生严重结肠炎。
  • FcγR-/-Rag1-/-小鼠对抗TNF效应无反应:其组织学结肠炎评分与给予对照抗体的FcγR-/-Rag1-/-小鼠一样严重。
  • 接受抗TNF的Rag1-/-小鼠结肠中CD206+巨噬细胞数量较给予对照抗体的Rag1-/-小鼠增加;在给予抗TNF的FcγR-/-Rag1-/-小鼠中,这些细胞数量与给予对照抗体的FcγR-/-Rag1-/-小鼠一样低。
  • 在人PBMCs中,抗TNF增加CD206+巨噬细胞数量,这需要FcγRIIIa表达;在具有低亲和力FcγRIIIa-158F基因型的PBMCs中,这些细胞数量减少。
  • 去岩藻糖基化阿达木单抗较对照阿达木单抗以更高亲和力结合人FcγRIIIa;加入PBMCs后形成更多CD206+巨噬细胞并减少T细胞增殖;在表达低亲和力FcγRIIIa的PBMCs中增加CD206+巨噬细胞数量;在结肠炎小鼠中,去岩藻糖基化抗TNF较对照抗TNF显著增加结肠CD206+巨噬细胞数量,并在组织学减轻结肠炎严重程度方面更有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Although tumor necrosis factor (TNF) antagonists reduce many clinical features of inflammatory bowel disease, complete mucosal healing occurs in fewer than 50% of patients. The Fc-region of monoclonal antibodies against TNF has immunosuppressive properties via effects on macrophage polarization. We examined the interaction between the anti-TNF Fc-region and Fcγ receptors (FcγR), and whether the absence of the Fc core fucose (which increases binding to FcγRIIIa) increases the efficacy of anti-TNF in mice with colitis. METHODS: We generated Rag1-/- mice that lack all activating FcγRs (FcγRI, FcγRIII, and FcγRIV; called FcγR-/-Rag1-/- mice). We produced hypo-fucosylated antibodies against mouse and human TNF (adalimumab). Colitis was induced in mice by transfer of CD4+CD45RBhi to FcγR-/-Rag1-/- or Rag1-/- littermates; mice were given different antibodies against TNF or isotype (control) antibodies and disease activity index scores were determined. Colon tissues were collected and analyzed by histology. Human peripheral blood mononuclear cells (PBMCs) were isolated from blood of healthy donors. T-cell proliferation and proportions of CD206+ (immune regulatory) macrophages were measured in mixed lymphocyte reactions. Human PBMCs were genotyped for FCGR3A158 (the FcγRIIIa-158F allotype displays a lower Fc binding affinity) using the TaqMan single nucleotide polymorphism genotype assay. RESULTS: Rag1-/- mice with colitis given anti-TNF had near complete mucosal healing and Rag1-/- mice given an isotype control antibody developed severe colitis. In contrast, FcγR-/-Rag1-/- mice were refractory to the effects of anti-TNF: their histological colitis scores were as severe as those from FcγR-/-Rag1-/- mice given a control antibody. Colons from Rag1-/- mice that received anti-TNF had an increased number of CD206+ macrophages compared with Rag1-/- mice given control antibody; in FcγR-/-Rag1-/- mice given anti-TNF these numbers were as low as FcγR-/-Rag1-/- given the control antibody. In human PBMCs, anti-TNF increased the number of CD206+ macrophages: this required expression of FcγRIIIa; numbers of these cells were reduced in PBMCs with the low-affinity FcγRIIIa-158F genotype. A hypo-fucosylated form of adalimumab bound human FcγRIIIa with a higher affinity than control adalimumab. When hypo-fucosylated adalimumab was added to PBMCs, a larger number of CD206+ macrophages formed and T-cell proliferation was reduced, compared with addition of a control adalimumab. Hypo-fucosylated adalimumab increased the number of CD206+ macrophages in PMBCs that expressed the low-affinity FcγRIIIa. In mice with colitis, hypo-fucosylated anti-TNF significantly increased the number of CD206+ macrophages in the colon compared with control anti-TNF and was more effective in reducing colitis severity as measured by histology. CONCLUSIONS: In a study of the in vitro and in vivo mechanisms of anti-TNF, we found FcγR engagement by anti-TNF to be required for reduction of colitis in mice and development of CD206+ macrophages. A hypo-fucosylated form of anti-TNF binds FcγRIIIa with higher affinity and induces development of CD206+ macrophages in human PBMCs, especially PBMCs that express low-affinity FcγRIIIa. Hypo-fucosylated anti-TNF might be more effective in patients with inflammatory bowel disease.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Bloemendaal FM, Levin AD, Wildenberg ME, et al. Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis. Gastroenterology. 2017. PMID: 28756234. doi:10.1053/j.gastro.2017.07.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。